Clinical Trials Results
Results for the search you initiated will be displayed below.
Trial Name
Brief Summary
This randomized phase III trial studies how well pembrolizumab works in treating patients
with bladder cancer that has spread from where it started to nearby tissue or lymph nodes.
Monoclonal antibodies recognizing and blocking checkpoint molecules can enhance the patient's
immune response and therefore help fight cancer. Pembrolizumab is one of the monoclonal
antibodies that block the PD-1 axis and can interfere with the ability of tumor cells to
grow.
This phase II trial studies how well cabozantinib works in combination with nivolumab and
ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other
places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab
and ipilimumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab
may work better in treating patients with genitourinary tumors that have no treatment options
compared to giving cabozantinib, nivolumab, or ipilimumab alone.
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab
followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by
nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread
to other parts of the body. The addition of cabozantinib to the usual treatment may make it
work better. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Drugs used in chemotherapy, such as cabozantinib, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. It is not yet known how well the combination of
cabozantinib and nivolumab after initial treatment with ipilimumab and nivolumab works in
treating patients with renal cell cancer that has spread to other parts of the body.
This phase II trial studies whether adding radium-223 dichloride to the usual treatment,
cabozantinib, improves outcome in patients with renal cell cancer that has spread to the
bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer
cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and
cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to
the bone, compared to cabozantinib alone.
This phase II trial studies how well gemcitabine together with pembrolizumab works in
treating patients with non-muscle invasive bladder cancer who are unresponsive to the BCG
vaccine. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine may delay
the return of bladder cancer for longer than gemcitabine alone.
This phase III trial compares survival in urothelial cancer patients who stop immune
checkpoint inhibitor treatment after being treated for about a year to those patients who
continue treatment with immune checkpoint inhibitors. Immunotherapy with monoclonal
antibodies, such as avelumab, durvalumab, pembrolizumab, atezolizumab, and nivolumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Stopping immune checkpoint inhibitors early may still make the
tumor shrink and patients may have similar survival rates as the patients who continue
treatment. Stopping treatment early may also lead to fewer treatment-related side effects, an
improvement in mental health, and a lower cost burden to patients.
This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib
and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with
prostate cancer that has spread to other places in the body (metastatic) and has become
resistant to testosterone-deprivation therapy (castration-resistant). Enzalutamide helps
fight prostate cancer by blocking the use of testosterone by the tumor cells for growth. Poly
adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors, such as rucaparib, fight
prostate cancer by prevent tumor cells from repairing their DNA. Giving enzalutamide and
rucaparib may make patients live longer or prevent their cancer from growing or spreading for
a longer time, or both. It may also help doctors learn if a mutation in any of the homologous
recombination DNA repair genes is helpful to decide which treatment is best for the patient.
This phase II/III trial compares the effect of adding chemotherapy before and after surgery
versus after surgery alone (usual treatment) in treating patients with stage II-III
gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the
tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it
easier for the surgeon to distinguish between normal and cancerous tissue. Giving
chemotherapy after surgery may kill any remaining tumor cells. This study will determine
whether giving chemotherapy before surgery increases the length of time before the cancer may
return and whether it will increase a patient's life span compared to the usual approach.
This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney)
with or without nivolumab in treating patients with kidney cancer that is limited to a
certain part of the body (localized). Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the
tumor smaller and reduce the amount of normal tissue that needs to be removed, and after
nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is
more effective than nephrectomy alone in treating patients with kidney cancer.
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy,
with or without cabazitaxel and prednisone, work in treating patients with
castration-resistant prostate cancer previously treated with docetaxel that has spread to
other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone
therapy using abiraterone acetate and antiandrogen therapy may fight prostate cancer by
lowering and/or blocking the use of androgens by the tumor cells. Drugs used in chemotherapy,
such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving abiraterone acetate and antiandrogen therapy with or without cabazitaxel
and prednisone may help kill more tumor cells.
This phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after
surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in
the blood. Testosterone is a hormone made mainly in the testes and is needed to develop and
maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. It
also plays role in prostate cancer development. Darolutamide blocks the actions of the
androgens (e.g. testosterone) in the tumor cells and in the body. Giving darolutamide with
ADT may work better in eliminating or reducing the size of the cancer and/or prevent it from
returning compared to ADT alone in patients with prostate cancer.
This phase II trial studies how well chemotherapy and radiation therapy alone works compared
to chemotherapy and radiation therapy plus MEDI4736 (durvalumab) immunotherapy in treating
bladder cancer which has spread to the lymph nodes. Drugs used in standard chemotherapy work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy
x-rays to kill tumor cells and shrink tumors. Immunotherapy with durvalumab may induce
changes in body's immune system and may interfere with the ability of tumor cells to grow and
spread. Giving chemotherapy and radiation therapy with the addition of durvalumab may work
better in helping tumors respond to treatment compared to chemotherapy and radiation therapy
alone.
This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation
therapy to see how well it works compared with antiandrogen therapy and radiation therapy
alone in treating patients with prostate cancer that has been removed by surgery. Androgen
can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen
made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink
tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving antiandrogen therapy and radiation therapy with or
without docetaxel after surgery may kill any remaining tumor cells.
This randomized phase III trial studies how well stereotactic body radiation therapy works
compared to intensity-modulated radiation therapy in treating patients with stage IIA-B
prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink
tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends
x-rays directly to the tumor using smaller doses over several days and may cause less damage
to normal tissue. Stereotactic body radiation therapy may work better in treating patients
with prostate cancer.
This phase II trial studies the side effects and best dose of niraparib, and to see how well
it works in combination with standard of care radiation therapy and hormonal therapy
(androgen deprivation therapy) in treating patients with prostate cancer that has a high
chance of coming back (high risk). Niraparib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Adding niraparib to the usual treatments of
radiation therapy and hormonal therapy may lower the chance of prostate cancer growing or
returning.
This phase III trial studies how well adding apalutamide, abiraterone acetate, and prednisone
to the usual hormone therapy and radiation therapy works compared to the usual hormone
therapy and radiation therapy in treating patients with node-positive prostate cancer after
surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors.
Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such
as apalutamide, may help stop or slow the growth of prostate cancer cell growth by blocking
the androgens. Abiraterone acetate blocks some of the enzymes needed for androgen production
and may cause the death of prostate cancer cells that need androgens to grow. Prednisone may
help abiraterone acetate work better by making tumor cells more sensitive to the drug. Adding
apalutamide and abiraterone acetate with prednisone to the usual usual hormone therapy and
radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading
or extend time without disease spreading compared to the usual approach.
This phase III trial compares less intense hormone therapy and radiation therapy to usual
hormone therapy and radiation therapy in treating patients with high risk prostate cancer and
low gene risk score. This trial also compares more intense hormone therapy and radiation
therapy to usual hormone therapy and radiation therapy in patients with high risk prostate
cancer and high gene risk score. Abiraterone acetate may help fight prostate cancer by
lowering the amount of testosterone made by the body. Apalutamide may help fight prostate
cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy
rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may
work the same at controlling prostate cancer compared to the usual 24 month hormone therapy
treatment in patients with low gene risk score. Adding abiraterone acetate and apalutamide to
the usual treatment may increase the length of time without prostate cancer spreading as
compared to the usual treatment in patients with high gene risk score.
This randomized phase III trial studies how well nutrition therapy works in improving immune
system in patients with bladder cancer that can be removed by surgery. Improving nutrition
before and after surgery may reduce the infections and other problems that sometimes occur
after surgery.
This phase III trial studies how well standard systemic therapy with or without definitive
treatment (prostate removal surgery or radiation therapy) works in treating participants with
prostate cancer that has spread to other places in the body. Addition of prostate removal
surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the
chance of the cancer growing or spreading.
This phase III trial studies how well chemotherapy and radiation therapy work with or without
atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation
therapy uses high energy rays to kill tumor cells and shrink tumors. Drugs used in
chemotherapy, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different
ways to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may
kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may
work better in treating patients with localized muscle invasive bladder cancer compared to
radiation therapy and chemotherapy without atezolizumab.
This phase III trial compares the effect of adding surgery to a standard of care
immunotherapy-based drug combination versus a standard of care immunotherapy-based drug
combination alone in treating patients with kidney cancer that has spread to other places in
the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab,
ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer,
and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to
remove the kidney, called a nephrectomy, is also considered standard of care; however,
doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the
addition of surgery to an immunotherapy-based drug combination works better than an
immunotherapy-based drug combination alone in treating patients with kidney cancer.
Clinical Trial Categories:
- Bone Cancer
- Brain Cancer
- Breast Cancer
- Cancer Control
- Companion Studies
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecology (GYN) Cancer
- Head and Neck Cancer
- Leukemia
- Lung Cancer
- Lymphoma (Hodgkin's Disease, Non-Hodgkin's Lymphoma)
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndrome (MDS)
- Other Cancer Protocols
- Pancreas Cancer
- Sarcoma
- Skin Cancer
- Symptom Management